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Monoclonal antibodies provide an attractive alternative to small-
molecule therapies for a wide range of diseases. Given the impor-
tance of G protein-coupled receptors (GPCRs) as pharmaceutical
targets, there has been an immense interest in developing therapeutic
monoclonal antibodies that act on GPCRs. Here we present the 3.0-Å
resolution structure of a complex between the human 5-hydroxy-
tryptamine 2B (5-HT2B) receptor and an antibody Fab fragment bound
to the extracellular side of the receptor, determined by serial femto-
second crystallography with an X-ray free-electron laser. The anti-
body binds to a 3D epitope of the receptor that includes all three
extracellular loops. The 5-HT2B receptor is captured in a well-defined
active-like state, most likely stabilized by the crystal lattice. The struc-
ture of the complex sheds light on the mechanism of selectivity in
extracellular recognition of GPCRs by monoclonal antibodies.
GPCR | active state | antibody recognition | X-ray free-electron laser |
serial femtosecond crystallography
Antibodies comprise hypervariable domains that evolve in re-sponse to antigenic stimuli, making them capable of selectively
binding virtually any macromolecule. Thanks to their potentially
high affinity, selectivity, long duration of action, and engineered
ability to penetrate the blood–brain barrier, monoclonal antibodies
(mAbs) provide an attractive alternative to small-molecule thera-
pies (1). G protein-coupled receptors (GPCRs) represent highly
attractive targets for therapeutic mAbs because of their involvement
in signal transduction, associated with many important diseases, and
their localization in the cell plasma membrane (2). Production of
mAbs against GPCRs, however, is a challenging task because of
difficulties in obtaining sufficient quantities of solubilized, purified,
and functional antigen. The most abundant class A GPCRs are
characterized by very small solvent-exposed domains, making pro-
duction of high affinity, selective mAbs even more difficult (3–7).
Furthermore, antibodies can recognize GPCRs in different func-
tional states, depending on the presence of agonists or antagonists
(8). Some mAbs can also recognize specific receptor conformations
independent of ligand presence, and there is a potential for iden-
tification of “biased” mAbs that can selectively guide receptor ac-
tivity to specific signaling pathways (3, 9). The first anti-GPCR
therapeutic mAb, mogamulizumab (KW-0761, POTELIGEO),
targeting the CCR4 receptor, was approved in 2012 in Japan for the
treatment of relapsed or refractory adult T-cell leukemia-lymphoma
(10). Currently, there are more than a dozen mAbs targeting ex-
tracellular sites of GPCRs in different stages of clinical trials for the
treatment of HIV, inflammation and immune disorders, athero-
sclerosis, cancer, and other major chronic diseases (11, 12).
To gain insight into the molecular basis of extracellular rec-
ognition of GPCRs by mAbs, we crystallized a complex between
the human 5-hydroxytryptamine 2B (5-HT2B) receptor bound to
the agonist ergotamine (ERG) and a selective antibody Fab
fragment, and solved its structure by serial femtosecond crystallog-
raphy (SFX) with an X-ray free-electron laser (XFEL). Given that
all previous structural information on GPCR recognition is limited
to Fabs/nanobodies bound to the intracellular side of the receptors
(13–17), this work provides unprecedented molecular insights into
the 3D antibody-binding extracellular epitope of the receptor.
Moreover, whereas previous 5-HT2B/ERG structures revealed con-
formational characteristics of an intermediate receptor activation
state (18, 19), the 5-HT2B/ERG-Fab structure captures the receptor
in a distinct active-like state, which shows extensive activation-related
changes throughout the receptor manifested in triggered “micro-
switches” and concerted movements of helices VI and VII.
Results
Antibody Binding Characterization. The monoclonal antibody
P2C2-IgG raised against human 5-HT2B receptor bound to ERG
was received as a gift from Bird Rock Bio, San Diego, CA.
P2C2 heavy and light chains were subcloned to enable expression
of a P2C2–Fab fragment in insect cells. ELISA experiments
confirmed that the purified P2C2–Fab binds selectively to the
extracellular epitope of the human 5-HT2B receptor, both in the
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presence (pKd = −8.50 ± 0.26) and absence (pKd = −8.86 ± 0.28)
of ERG (Fig. S1A).
Structure of the 5-HT2B/ERG-Fab Complex. For structural studies, we
used the same engineered construct of the human 5-HT2B receptor as
the one previously used to obtain 5-HT2B/ERG structures (18, 19).
Size-exclusion chromatography (SEC) and pull-down assays con-
firmed formation of a complex between purified receptor and anti-
body (Fig. S2). The 5-HT2B/ERG-Fab structure was determined at
3.0-Å resolution (Fig. 1, Fig. S3, and Table S1). The complex was
crystallized in lipidic cubic phase (LCP) (Fig. S3 A and B) in a P21
space group, with two complexes (chains ABC and DEF) per
asymmetric unit (Fig. S4). Because both structures are nearly identical
(rmsdCα ∼0.3 Å for the receptor and ∼1.3 Å for the whole complex)
(Fig. S5), we hereafter focus on the description of the ABC complex.
Specific Interactions Between Fab and 5-HT2B. The Fab forms extensive
interactions with all three extracellular loops (ECLs) of the
receptor with a total buried surface of 945 Å2 (Figs. 1 and 2 and
Tables S2 and S3). On the Fab side, interactions involve all three
complementarity-determining regions (CDR) of the heavy chain
(CDR-H1, CDR-H2, and CDR-H3), as well as CDR-L1 and CDR-
L3 of the light chain. The longest CDR-H3 loop (21 residues)
adopts the shape of a β-hairpin that extensively interacts with a part
of ECL2, together forming a three-stranded β-sheet (Fig. 1A). In-
terestingly, the tip of CDR-H3 extends toward the lipid membrane,
likely anchoring its hydrophobic residues Ile106 and Leu107 in the
membrane near helices III and IV of the receptor. CDR-
H2 interacts mostly with ECL2 and ECL3. Asn50 (CDR-H2) forms
a hydrogen bond with Asp198ECL2, Tyr52 (CDR-H2) with
Glu212ECL2, and Ser54 (CDR-H2) with Gln3557.28 (Fig. 1B). CDR-
H1 interacts only with ECL2 and has the least number of contacts.
Thr30 (CDR-H1) makes a hydrogen bond with Glu212ECL2, and
Trp33 (CDR-H1) makes a nonpolar contact with Asp198ECL2 (Fig.
1C). The Fab light chain, specifically CDR-L3, also forms multiple
hydrogen bonds and salt bridges with the receptor (Fig. 1D). On the
receptor side, one of the key residues for Fab recognition is
Asp198ECL2 (Fig. 1 B–D). Its acidic side chain protrudes into the
interface between the light and heavy chains of Fab, interacting with
both of them. Asp198ECL2 forms a salt bridge with Arg90 (CDR-
L3), and hydrogen bonds with Tyr93 (CDR-L3), Asn50 (CDR-H2),
and His35 (CDR-H1), as well as makes a hydrophobic contact with
Trp33 (CDR-H1). Mutational studies using ELISA further con-
firmed the importance of Asp198ECL2 for binding of P2C2–Fab,
which showed at least three orders-of-magnitude decreased affinity
of Fab binding to the D198N mutant (Fig. S1B).
Strong interactions between ECL2 of the 5-HT2B receptor and
the Fab lead to a distinct ECL2 conformation, compared with
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Fig. 1. Structure of the complex between 5-HT2B/ERG and an antibody Fab fragment. Overall view of the complex with 5-HT2B (green), Fab light chain (teal),
and Fab heavy chain (magenta). Red and blue lines indicate the extracellular and intracellular membrane boundaries, respectively, as defined in the Ori-
entation of Proteins in Membranes database (opm.phar.umich.edu/). The ligand ERG is shown as spheres with carbon atoms colored blue. Zoom-in panels
show details of interactions between the receptor and (A) CDR-H3, (B) CDR-H2, (C) CDR-H1, and (D) CDR-L1 and CDR-L3 of the P2C2–Fab. Hydrogen bonds and
salt bridges are shown as yellow dash lines. Stereo views of 2mFo–DFc electron density maps contoured at 1 σ (gray mesh) for the interaction region between
CDR-H3 of Fab and ECL2 of 5-HT2B (E) and for the ligand-binding pocket (F).
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those previously observed in the 5-HT2B/ERG and 5-HT2B/LSD
structures (20) (Fig. S6A). Because ECL2 is sandwiched between
the transmembrane helical bundle and Fab, it adopts a more ordered
conformation in the 5-HT2B/ERG-Fab structure with better-defined
electron density compared with ECL2 in the 5-HT2B/ERG structure.
Because ECL2 of the 5-HT2B receptor has previously been shown
to play a critical role in ligand binding and receptor signaling (20),
these molecular insights could be used to guide the development
of pharmacological antibodies.
Fab Binding Selectivity Analysis.A structure-based alignment of 5-HT2B
receptor with the closest subfamily members, 5-HT2A and 5-HT2C
(Fig. S7 and Tables S2 and S3), revealed that although the
overall conservation of the extracellular region is relatively high,
most receptor residues involved in interactions with the P2C2–Fab
are unique for the 5-HT2B subtype. Moreover, variations in the
amino acid length of ECL2 and ECL3 and a unique Pro202ECL2
residue suggest substantial deviations in the backbone conformation
of the extracellular region between 5-HT2B and the other two sub-
family members. To confirm the importance of Pro202ECL2 for the
receptor–Fab interaction, we generated two point mutants (P202A,
P202W) to destabilize the ELC2 conformation. Both mutants sub-
stantially decreased P2C2–Fab binding affinity, with P202W exhib-
iting a stronger effect, as expected (Fig. S1B). A broader analysis of
the whole 5-HT family shows even more dramatic variability in the
ECL length and sequence (Fig. S7). These results provide a struc-
tural basis for P2C2’s selectivity for the 5-HT2B receptor (Fig. S1 C–
F), and suggest a path toward the rational design of receptor-specific
immunological tools for the study of GPCRs.
Active-Like 5-HT2B Receptor Conformation. The current crystal structure
of the 5-HT2B/ERG-Fab complex captures the receptor in a
distinct active-like conformational state, compared with the
previously published structures of 5-HT2B/ERG (18, 19) (Fig. 3).
The common activation mechanism of class A GPCRs involves an
outward tilt of helix VI and an inward movement of helix VII on
the intracellular side of the receptor, forming a cleft to accom-
modate binding of G protein or β-arrestin transducers (13, 21–23).
The previous structure of 5-HT2B/ERG (PDB ID code 4NC3)
shows helix VI in a partially activated state with an outward shift
of ∼3 Å, compared with the inactive structure of β2AR (PDB ID
code 2RH1). Using the same comparison, the current structure of
5-HT2B/ERG-Fab reveals a much larger 6.7-Å shift of helix VI at
the residue Glu3196.30, which is the most pronounced motion of
helix VI observed in all active-like GPCR structures without in-
tracellular binding partners (24). Concomitantly, helix V follows
the motion by shifting about 2.9 Å, as measured at Leu2445.65 (Fig.
3A). Helix VII is also known to undergo rearrangements during
activation. In 5-HT2B/ERG-Fab, we see a similar inward move-
ment and distortion in the conserved NPxxY motif of helix VII,
with an even greater inward shift in the key Tyr3807.53 residue than
in the previous 5-HT2B/ERG structure.
Upon receptor activation, the large-scale helical rearrangements
are accompanied by conformational changes in conserved micro-
switches (25). The most important microswitches in class A GPCRs
are the PIF, D(E)RY, and NPxxY motifs. The PIF motif is one of
the central conserved microswitches that are present in most ami-
nergic receptors, including 5-HT2B (26). Activation of this micro-
switch includes an inward shift of Pro5.50, a rotamer switch in Ile3.40,
and a side-chain rotation of the Phe6.44 residue (17, 27). Al-
though 5-HT2B/ERG showed an active-like conformation of the
Pro2295.50 and Ile1433.40 residues, Phe3336.44 was found to be in an
inactive conformation. In the present structure, all three PIF residues,
including Phe3336.44, are in a well-defined active-like state similar to
the one found in the fully active β2AR-Gs complex (Fig. 3B).
In the ground inactive state of GPCRs, the Arg3.50 side chain of
the D(E)RY motif forms a salt bridge with the neighboring Asp3.49.
The salt bridge also stays intact in most GPCR structures bound to
agonists and captured in partially activated states. Upon full receptor
activation, however, the Asp3.49–Arg3.50 salt bridge breaks and Arg3.50
adopts an extended conformation ready for interactions with the
C-terminal helix of the Gα subunit or with the finger loop of arrestin.
The 5-HT2B/ERG-Fab structure reveals a broken salt bridge and an
extended conformation of the Arg3.50 side chain, suggesting that the
D(E)RY switch in our structure is fully activated (Fig. 3C).
The NPxxY motif is located on the intracellular side of helix
VII. Tyr7.53, which is a part of this motif, is a highly conserved
residue that is believed to serve as a major activation microswitch
in class A GPCRs. In all of the inactive structures of GPCRs, this
residue points to helices I, II, and VIII. Upon activation, the cy-
toplasmic part of helix VII moves further into the transmembrane
receptor core along with a side-chain rotation of Tyr7.53, where it
interacts with helices III and VI. The previous 5-HT2B/ERG
structure showed an active-state conformation of the NPxxY
motif backbone, similar to that found in active-like states of β2AR
and the A2A adenosine receptor (21, 27). However, in contrast
to all other active-state structures, the Tyr3807.53 side chain in the
5-HT2B/ERG structure adopted a different rotamer, with its tip
pointed down toward the intracellular part of the protein. In the
current 5-HT2B/ERG-Fab structure, such a downward-facing
conformation of Tyr3807.53 would be blocked by the extended
conformation of Arg3.50 of the DRY motif. Instead, the side chain
of Tyr3807.53 in 5-HT2B/ERG-Fab points up toward the extracel-
lular side, whereas the backbone of this residue is shifted a further
2-Å inward, similar to the fully activated β2AR-Gs structure (Fig.
3D). This observation suggests coordinated switching of both
DRY and NPxxY motifs in the 5-HT2B/ERG-Fab structure, con-
sistent with an active-like conformation of the 5-HT2B receptor.
Discussion
The approved cancer drug mogamulizumab (KW-0761, POTELI-
GEO) (10), as well as most other GPCR antibodies in clinical de-
velopment, target either linear epitopes in long N-terminal regions
of chemokine receptors or extracellular domains of nonclass A
GPCRs. At the same time, the small size of the extracellular region
of many class A GPCRs represents a special challenge for antibody
discovery, as it may require recognition of a nonlinear structural
epitope for high affinity and subtype selectivity. The structure of
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Fig. 2. Overall structure of the 5-HT2B/ERG-Fab complex and the binding
interface between Fab and 5-HT2B/ERG. (A) Two side views of the 5-HT2B/
ERG-Fab complex in a surface representation. Red and blue lines correspond
to the extracellular and intracellular membrane boundaries respectively, as
defined in the Orientation of Proteins in Membranes database (opm.phar.
umich.edu/). (B) Interacting surfaces of 5-HT2B/ERG and Fab. 5-HT2B receptor
is shown in light green, ERG is shown as spheres with blue carbons, Fab
heavy chain is in light magenta, Fab light chain is in light cyan. Interacting
residues are highlighted in bold colors.
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the P2C2–Fab bound to a prototypical class A serotonin receptor,
5-HT2B, described in this study, provides a structural template for
high-affinity and high-selectivity recognition of such 3D epitopes in
GPCRs. Moreover, molecular insights into binding of antibodies to
the 5-HT2B receptor, a bona fide drug target in the prevention of
valvular heart disease and primary pulmonary hypertension (28),
could also provide an important first step in the generation of
immunological therapies.
The recognition interface covers a larger part of the solvent-
exposed extracellular region of the receptor, involving all three
ECLs. ECLs are the most variable regions in GPCRs, and the
vast majority (16 of 20) of the contact side chains are different
between 5-HT2B and its closest subtypes, 5-HT2A and 5-HT2C,
assuring high selectivity of recognition.
In addition to highly selective interactions, which are defined
as those that include unique to the 5-HT2B receptor residues, the
structure of the 5-HT2B/ERG-Fab complex revealed several
nonspecific interactions, such as those involving only receptor
backbone atoms, which may be common for other antibodies
recognizing extracellular regions of class A GPCRs, and thus can
be used for antibody design. One such major interaction is the
formation of a three-stranded β-sheet with a network of strong
backbone–backbone contacts between CDR-H3 and ECL2. Ex-
tended loops or β-hairpin conformations are common for many
class A GPCRs, and they can form potential common sites for
initial antibody recognition. Another interesting feature of the
P2C2–Fab interaction is the apparent membrane anchoring of
the two hydrophobic side chains at the tip of the CDR-H3 loop.
Whereas I106 forms hydrophobic contacts with P1914.61 and
A1303.27, L107 has no contacts with the receptor, and it is likely
to interact nonspecifically only with lipid molecules (Fig. S6B). It
is possible that membrane anchoring of these residues precedes
the full engagement of the Fab with 5-HT2B, thus reducing the
diffusion search from 3D bulk solvent to 2D membrane surface.
Unlike the previously solved structures of the 5HT2B/ERG com-
plex, which were captured in a partially activated state (18, 19), the
5-HT2B/ERG-Fab structure shows a fully active-like conformation of
the receptor, with all attributes of the active state, including very
pronounced dislocations of helices VI and VII and activation of all
conserved microswitches. Analysis of the Fab contacts, however,
does not suggest any substantial conformational changes in the ex-
tracellular parts of the 5-HT2B transmembrane helices compared
with the 5HT2B/ERG structures. The largest observed shift involves
a ∼1.5-Å outward displacement of the helix V tip, which is not
consistent with the inward shift of this helix observed in some other
active structures of related aminergic receptors, such as β2AR (13,
25). Accordingly, P2C2–Fab did not affect ligand binding (LSD and
ERG), Gq-induced calcium flux, or β-arrestin recruitment (Fig. S8),
suggesting that the active-like receptor conformation captured in the
crystal structure was likely stabilized by the crystal packing rather
than by direct receptor–Fab interactions.
In conclusion, this work represents the structure of an antibody
selectively bound to the extracellular surface of a GPCR, shedding
light on the structural basis of receptor recognition. Highly se-
lective mAbs directed against extracellular epitopes of GPCRs are
of tremendous scientific interest for studying receptor localization,
structure, and function, as well as providing a platform for the
development of therapeutic applications (11, 12).
Materials and Methods
Expression and Purification of P2C2–Fab. P2C2–Fab was obtained by Fab
phage display of libraries derived from immunized mice using Bird Rock Bio’s
proprietary iCAPS technology. The antibody uses an IGKV4/5 light chain and
a VH1 heavy chain.
P2C2–Fab was expressed in Spodoptera frugiperda (Sf9) insect cells (Ex-
pression Systems). Fab heavy and light chains were cloned into a modified
bicistronic version of the pFastBac vector (Wilson laboratory, The Scripps Re-
search Institute). The expression cassette contained a honey bee melittin signal
sequence at the N terminus of the light chain, and a gp67 signal sequence at
the N terminus and His-tag at the C terminus of the heavy chain of the Fab.
The construct was expressed in Sf9 cells using the Bac-to-Bac Baculovirus Ex-
pression System. Sf9 cells at density of 2–3 × 106 cells/mL were infected with
P1 virus at a multiplicity of infection of 3. Cell culture supernatant was harvested
48 h postinfection by centrifugation, filtered using a 0.2-μm filter, and used
immediately for Fab purification. His-tagged Fabwas captured from supernatant
using TALON IMAC resin (Clontech) for 3 h at 4 °C. TALON resin was washed
with 20 mM Tris, 100 mM NaCl, 10 mM imidazole, pH 7.5 buffer, and Fab eluted
from the resin using the same buffer containing 250 mM imidazole. Purified Fab
was buffer exchanged into 50 mM Hepes, 50 mM NaCl, pH 7.5 using a PD-
10 column, and purified on a HiTrap SP HP column (GE Healthcare Life Sciences)
using a linear NaCl gradient. Eluted fractions were analyzed by SDS/PAGE,
pooled, concentrated, and further purified on a Superdex75 column. Fab-
containing fractions were pooled and concentrated using a 30-KDa cut-off
concentrator for binding assays and crystallization trials, as described below.
Receptor Expression and Purification. The 5-HT2B expression construct was
codon-optimized, synthesized by DNA2.0, and subcloned into a modified
pFastBac1 vector (Invitrogen) through 5′AscI and 3′FseI restriction sites.
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Fig. 3. Receptor activation-related features of the 5-HT2B/ERG-Fab complex. Superposition of β2AR-Gs active state (magenta; PDB ID code 3SN6), β2AR in-
active state (dark blue; PDB ID code 2RH1), 5-HT2B/ERG (light blue; PDB ID code 4IB4), and 5-HT2B/ERG-Fab complex (green). (A) View from the intracellular
side. (B) PIF motif. (C) D(E)RY motif. (D) NPxxY motif. Major activation-related rearrangements observed in β2AR are shown as red arrows.
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Thermostabilized apocytochrome b562 RIL (BRIL) from Escherichia coli
(M7W, H102I, R106L) was inserted into ICL3 replacing the original residues
Tyr249-Val313. N-terminal residues 1–35 and C-terminal residues 406–481
were truncated from the original receptor gene. Additionally, a thermo-
stabilizing M1443.41W mutation was introduced. The pFastBac vector con-
tained an expression cassette with a hemagglutinin (HA) signal sequence
followed by a FLAG tag at the N terminus, and a PreScission protease site
followed by a 10× His tag at the C terminus.
The 5-HT2B receptor expression and purification was performed as de-
scribed previously (18). In brief, the virus production and protein expression
were performed using Bac-to-Bac Baculovirus Expression System (Invitrogen)
in Sf9 insect cells. Expression of the 5-HT2B receptor was carried out by in-
fection of Sf9 cells at a cell density of 2–3 × 106 cells/mL, with P2 virus at a
multiplicity of infection of 5. Insect cells were harvested by centrifugation
48 h after infection.
Insect cells were disrupted by thawing frozen cell pellets in a hypotonic
buffer. Extensive washing of the isolated membranes was performed using
hypertonic buffer containing 1 M NaCl to remove membrane-associated pro-
teins. Purified membranes were resuspended in buffer containing 10 mM
Hepes, pH 7.5, 10 mM MgCl2, 20 mM KCl, 150 mM NaCl, 100 μM ERG (Sigma),
2 mg/mL iodoacetamide, and EDTA-free complete protease inhibitor mixture
tablets (Roche), and incubated at room temperature for 1 h. Membranes were
then solubilized in 10 mMHepes, pH 7.5, 150 mMNaCl, 1% (wt/vol) n-dodecyl-
β-D-maltopyranoside (DDM, Anatrace), 0.2% (wt/vol) cholesteryl hemisuccinate
(CHS, Sigma), 50 μM ERG, and EDTA-free complete protease inhibitor mixture
tablets (Roche) for 2 h at 4 °C. Cell debris were removed by ultracentrifugation.
Protein was bound to TALON IMAC resin (Clontech) overnight at 4 °C in the
presence of 20 mM imidazole and 800 mM NaCl. After incubation, the resin
was then washed with 10 column volumes (CV) of Wash Buffer I [50 mM
Hepes, pH 7.5, 800 mM NaCl, 0.1% (wt/vol) DDM, 0.02% (wt/vol) CHS, 20 mM
imidazole, 10% (vol/vol) glycerol, and 50 μM ERG], followed by 5 CV of
Wash Buffer II [50 mM Hepes, pH 7.5, 150 mM NaCl, 0.05% (wt/vol) DDM,
0.01% (wt/vol) CHS, 10% (vol/vol) glycerol, and 50 μMERG]. Protein was eluted in
5 CV of Wash Buffer II + 250 mM imidazole and concentrated to 0.5 mL. Imid-
azole was removed using desalting via PD MiniTrap G-25 columns (GE Health-
care). Removal of the C-terminal 10× His-tag was performed overnight by
addition of His-tagged PreScission protease (homemade). Protease, cleaved His-
tags, and uncleaved protein were removed by the reverse IMAC.
Characterization of the Fab–Receptor Complex. Binding of P2C2–Fab to human
5-HT2B receptor was confirmed by ELISA, Flow cytometry, analytical SEC
(aSEC) and pull-down assays.
ELISA. Crystallized construct of 5-HT2B was expressed in Sf9 cells and purified
similarly to crystallization protocol. To compare binding of P2C2–Fab in the
presence and absence (apo) of ERG, 5-HT2B at concentration 100 μg/mL was
added to anti-FLAG M2 magnetic beads (Sigma) distributed into 96-well plates
(Corning), resulting in 100 μL of protein solution per 25 μL of beads per well.
Plates were incubated for 1 h at room temperature to ensure receptor binding.
After incubation, the plates were washed with Wash Buffer (50 mM Hepes pH
7.5, 300 mM NaCl, 0.025% DDM, 0.005% CHS), blocked with 1% (wt/vol) BSA in
Wash Buffer solution and incubated with increasing concentrations of purified
P2C2–Fab for 1 h at room temperature. Plates were then washed with Wash
Buffer two to three times and incubated with anti-human Fab-HRP secondary
antibody (Sigma) for 1 h. Unbound antibody was removed by washing with
Wash Buffer and 1-Step Ultra TMB (Thermo Fisher Scientific) added to develop
the color. The reaction was stopped by adding 2 M sulfuric acid solution and
absorbance in each well was measured at 450 nm. To determine the effect of
point mutations on the binding of P2C2–Fab, we have used precoated anti-FLAG
96-well plates (Sigma) to bind 5-HT2B. The rest of the protocol was performed
exactly as above. The data were analyzed in Graphpad Prism 5.0.
Flow cytometry. Full-length or N-terminal truncated (44 residues) human
5-HT2B receptor was stably transfected into TRex CHO cells (Thermo Fisher
Scientific). Binding of P2C2–Fab to the cell surface-expressed receptor was
determined 24 h post tetracycline induction. Cells suspended in BSA stain
buffer (BD Pharmingen) were incubated with P2C2–Fab on ice for 1 h,
washed to remove unbound antibody, followed by incubation with goat
anti-human IgG-FITC secondary antibody (Pierce) for 30 min on ice. The cells
were again washed and fluorescence measured using a Guava cytometer.
aSEC. To test the complex formation using SEC, the crystallized construct of
5-HT2B in complex with ERG purified in DDM/CHS detergent micelles was
incubated with purified P2C2–Fab and incubated on ice for 2 h. The 5-HT2B/
Erg, P2C2–Fab, and 5-HT2B/Erg + P2C2–Fab were then injected onto a SEC
column (Sepax Technologies) using an HPLC system (Agilent Technologies) to
check for 5-HT2B/ERG-Fab complex formation.
Pull down. Fifty micrograms 5-HT2B/Erg; 50 μg His-tagged P2C2–Fab; and 50 μg
5-HT2B/Erg preincubated with 50 μg His-tagged P2C2–Fab were incubated
with TALON resin for 2 h at 4 °C. Eluate and flow-through fractions were
then analyzed by SDS/PAGE.
Radioligand saturation and competition assays. Membranes from HEK293 cells
expressing 5-HT2B receptor were used for all binding assays, and experiments
were performed using standard binding buffer (50 mM Tris, 10 mM MgCl2,
0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) for 4 h at 37 °C. For
saturation binding, membranes preincubated for 30 min with or without
1 μM of P2C2–Fab were incubated with increasing concentrations of [3H]-LSD
(Perkin-Elmer), and nonspecific binding was determined by addition of
10 μM methiothepin. For competition binding, membranes preincubated
for 30 min with or without 1 μM of P2C2–Fab were incubated with 0.75 nM
[3H]-LSD (Perkin-Elmer) and different dilutions of ERG. After incubation,
plates were harvested by vacuum filtration onto 0.3% polyethyleneimine
presoaked 96-well filter mats (Perkin-Elmer) using a 96-well Filtermate har-
vester, followed by three washes of cold wash buffer (50 mM Tris pH 7.4).
Scintillation (Meltilex) mixture (Perkin-Elmer) was melted onto dried filters
and radioactivity was counted using a Wallac Trilux MicroBeta counter
(Perkin-Elmer). Data were normalized and analyzed in Graphpad Prism
5.0 using either “One site–Specific binding” or “One site–Fit Ki” for satu-
ration and competition binding experiments, respectively.
Calcium flux assay. A stable cell line for the 5-HT2B receptor was generated
using the Flp-In 293 T-Rex Tetracycline inducible system (Invitrogen).
Tetracycline-induced cells were seeded in 384-well poly-L-lysine–coated
plates at a density of 20,000 cells per well in 40 μL DMEM containing 1%
dialyzed FBS 18–20 h before the calcium flux assay. On the day of the assay,
media was removed, and the cells were incubated for 1 h at 37 °C in 20 μL
per well Fluo-4 Direct dye (Invitrogen) reconstituted in FLIPR buffer (1×
HBSS, 2.5 mM probenecid, and 20 mM Hepes, pH 7.4) plus 10 μL per well of
either 4 μM P2C2–Fab in FLIPR buffer or just FLIPR buffer. After dye loading,
cells were placed in a FLIPRTETRA fluorescence imaging plate reader (Molec-
ular Dynamics). Drug dilutions were prepared at 4× final concentration in
drug buffer (1× HBSS, 20 mM Hepes, 0.1% BSA, 0.01% ascorbic acid, pH 7.4)
and aliquoted into 384-well plates and placed in the FLIPRTETRA for drug
stimulation. The fluidics module and plate reader of the FLIPRTETRA were
programmed to read baseline fluorescence for 10 s (one read per second),
then 10 μL of drug per well was added and read for 4 min (one read per
second). Fluorescence in each well was normalized to the average of the first
10 reads (i.e., baseline fluorescence). Then, the maximum-fold increase,
which occurred within the first 60 s after drug addition, was determined and
fold over baseline was plotted as a function of drug concentration. Data
were normalized to percent 5-HT stimulation and analyzed using “log(ag-
onist) vs. response” in Graphpad Prism 5.0.
Tango arrestin recruitment assay. The 5-HT2B receptor Tango construct was
designed and assays were performed as previously described (29). HTLA cells
expressing tobacco etched virus-fused β-Arrestin2 (kindly provided by
Richard Axel, Columbia University, New York) were transfected with the
5-HT2B receptor Tango construct. The next day, cells were plated in DMEM
supplemented with 1% dialyzed FBS in poly-L-lysine–coated 384-well white
clear-bottom cell-culture plates at a density of 5,000 cells per well in a total
volume of 40 μL. The cells were incubated for at least 6 h before receiving
drug stimulation. Either 10 μL of 6 μM P2C2–Fab in drug buffer (1× HBSS,
20 mM Hepes, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) or just drug buffer was
added to the cells before 10 μL of 6× drug solution was added to the cells for
overnight incubation. The next day, media and drug solution were removed
and 20 μL per well of BrightGlo reagent (purchased from Promega, after
1:20 dilution in drug buffer) was added. The plate was incubated for 20 min
at room temperature in the dark before being counted using a luminescence
counter. Results (relative luminescence units) were plotted as a function of
drug concentration, normalized to percent 5-HT stimulation, and analyzed
using “log(agonist) vs. response” in GraphPad Prism 5.0.
Crystallization in LCP. The 5-HT2B/ERG-Fab complex formation was achieved
by mixing 5-HT2B/ERG (2-5 mg/mL) with Fab (5–10 mg/mL) in 1:1.2 mol ratio
at 4 °C for 2 h. The complex was further concentrated to 40 mg/mL and
crystallized using an LCP approach (30).
The 5-HT2B/ERG-Fab complex was reconstituted in LCP by mixing the protein
solution with monopalmitolein (9.7 MAG, purchased from Nu-Check Prep)
doped with 10% cholesterol in 1:1 (protein:lipid) vol/vol ratio using a syringe
mixer (31). Initial crystallization trials were set up in 96-well glass sandwich plates
(Marienfeld) using a Formulatrix NT8-LCP robot by dispensing 40 nL of protein-
laden LCP per well and overlaying it with 800 nL of precipitant solution. Crys-
tallization hits from plate format were further optimized for crystallization
in syringes. Microcrystals for XFEL data collection were obtained in several
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Hamilton gas-tight syringes using the published protocols (32). Approxi-
mately 5 μL of protein-laden LCP were slowly injected as a continuous fil-
ament into a 100-μL syringe filled with 60 μL of precipitant solution. The
final precipitant composition that resulted in showers of <10-μm crystals
was 0.1 M Tris·HCl pH 7.7, 60 mM sodium/potassium tartrate, 25% (vol/vol)
PEG400.
SFX. LCP-SFX data collection was performed using the CXI instrument at the
Linac Coherent Light Source (LCLS) at SLAC National Accelerator Laboratory.
The LCLS was operated at a wavelength of 1.56 Å (7.95 keV) delivering indi-
vidual X-ray pulses of 35-fs duration and 3.9 × 1011 photons per pulse focused
into a spot size of ∼1.5 μm in diameter using a pair of Kirkpatrick-Baez
mirrors. Protein microcrystals in LCP medium were injected at room tem-
perature inside a vacuum chamber into the beam focus region using the
LCP injector with a 50-μm diameter nozzle at a flow rate of 0.2 μL/min.
Microcrystals ranged in size from 1 to 10 μm. The instrument was operated
at a repetition rate of 120 Hz and the diffraction data were recorded with
the 2.3 Megapixel Cornell-SLAC Pixel Array Detector. The beam was at-
tenuated to 9% (3.5 × 1010 ph per pulse) of full intensity to avoid detector
saturation.
A total number of 1,877,040 snapshots were collected, of which 193,328
were identified as potential single crystal hits with more than 15 potential Bragg
peaks using Cheetah (33), corresponding to an average hit rate of 10.3%.
Autoindexing and structure factor integration of the crystal hits were performed
using Monte Carlo integration routine with “pushres 1.5” option implemented
in CrystFEL (v0.6.2) (34). Peak detection parameters were extensively optimized
for Cheetah (33) and experimental geometry was refined for CrystFEL (34). The
overall time of data collection from seven samples with a total volume of 55 μL
was about 4.5 h and yielded 52,291 indexed patterns (indexing rate 27.0%).
Structure Solution and Refinement. The SFX data were initially indexed and
merged in the orthorhombic Laue classmmm. However, extensive molecular
replacement (MR) trials failed to find a solution for either 5-HT2B or Fab in
any space group belonging to this symmetry. To account for possibility of a
pseudomerohedral twinning leading to a higher Laue symmetry, the Laue
symmetry was reduced to 2/m, and a MR solution was found in the primitive
monoclinic P21 space group with two 5-HT2B/ERG-Fab complexes per asym-
metric unit. MR was performed by Phaser (35) in a step-wise manner: first,
two molecules of 5-HT2B were placed using previously solved structure (PDB
ID code 4NC3) without BRIL, then the constant parts of two Fabs were added
followed by the variable subunits of the Fabs (PDB ID code 3QO1). BRIL
molecules (from PDB ID code 4NC3) were added during the last additional
Phaser run. After the structure was solved by MR, the initial model was built
by Phenix.Autobuild (36) and further completed by manual adjustments in
Coot (37) and iterative refinement in Phenix.refine (38) and Buster (39) using
one TLS group per chain.
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